A Phase I/II Study of PR1 (NSC 698102) Human Leukemia Peptide Vaccine With Montanide ISA 51 (NSC 675756) or Montanide ISA 51 VG (NSC 737063) Adjuvant.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs PR1 peptide vaccine (Primary) ; Montanide ISA-51
Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

04 Jan 2013 Planned number of patients changed from 66 to 69 as reported by ClinicalTrials.gov.
29 Feb 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
29 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com